Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript

Rhonda Farnum: I can take that, Rick?

Rick Winningham: Yes, go ahead.

Rhonda Farnum: So, you’ve hit the guiding factor head-on. Publication is vastly important, and the team will move as expeditiously as possible to ensure we are published in the highest standard peer-reviewed journal so that we will then have the ability to educate on those data.

Eva Xia Privitera: Great. Thank you.

Rhonda Farnum: And given the variability on timelines associated with individual peer-reviewed journals, I can’t really speak to one specifically.

Eva Xia Privitera: Thank you.

Operator: Thank you. It appears we have no further questions on the phone. I’d now like to turn the conference back to Mr. Winningham for, please go ahead, sir.

Rick Winningham: Yes, thank you very much. I’d like to thank everyone for joining us today. We’re pleased with the progress that we made this quarter. We look forward to continuing that progress in the fourth quarter and into 2024 as we really align resources behind the two growth drivers of the company, YUPELRI and ampreloxetine. So, thank you very much for joining us, and have a great day.

Operator: Thank you. This concludes today’s conference call. We thank you for your participation. You may now disconnect.